TVARDI THERAPEUTICS INC (TVRD:NASDAQ)
$3.16 -0.06 (-1.8634%)
Analysed TVARDI THERAPEUTICS INC (TVRD:NASDAQ) News Sources
Sector Update: Health Care Stocks Fall Late Afternoon
20-04-2026
yahoo.com
Tvardi Therapeutics to Participate in the Raymond James Biotech Innovation Symposium
02-04-2026
yahoo.com
Tvardi Therapeutics Announces Fourth Quarter and Full-Year 2025 Results and Provides Business Update
31-03-2026
yahoo.com
Tvardi Therapeutics to Participate in Upcoming Investor Conferences
12-02-2026
yahoo.com
We're Keeping An Eye On Tvardi Therapeutics' (NASDAQ:TVRD) Cash Burn Rate
07-02-2026
yahoo.com
Tvardi Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
08-01-2026
yahoo.com
Tvardi Therapeutics Announces Further Phase 2 REVERT IPF Data, Expanding Clinical Insights
08-01-2026
yahoo.com
Tvardi (TVRD) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
18-11-2025
yahoo.com
Tvardi Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference
18-11-2025
yahoo.com
Tvardi: Q3 Earnings Snapshot
13-11-2025
yahoo.com
What is the current price of TVARDI THERAPEUTICS INC (TVRD:NASDAQ)?
The current price of TVARDI THERAPEUTICS INC (TVRD:NASDAQ) is $3.16.
TVARDI THERAPEUTICS INC (TVRD:NASDAQ) absolute price change since previous trading day?
The absolute price change of TVARDI THERAPEUTICS INC (TVRD:NASDAQ) since the previous trading day is $-0.06.
TVARDI THERAPEUTICS INC (TVRD:NASDAQ) percentage price change since previous trading day?
The percentage price change of TVARDI THERAPEUTICS INC (TVRD:NASDAQ) since the previous trading day is -1.8634%.
What is the most recent average sentiment score for TVARDI THERAPEUTICS INC (TVRD:NASDAQ)?
The most recent average sentiment score for TVARDI THERAPEUTICS INC (TVRD:NASDAQ) is 83 out of 100.
What is the most recent average sentiment for TVARDI THERAPEUTICS INC (TVRD:NASDAQ)?
The most recent sentiment for TVARDI THERAPEUTICS INC (TVRD:NASDAQ) is .
SEC-8K** Filing Available For TVARDI THERAPEUTICS INC (TVRD:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.